Bioton reported purchasing a 21.3% stake in Indar, a company controlling some 70% of the Ukrainian insulin market. The annual revenues of Indar amount to some PLN 50m, compared to Bioton's sales revenues of PLN 151.7m in 2005. The value of the transaction was not disclosed. We believe the news could have a positive impact on Bioton's share price.